Items where authors include "Lindemann, J.P.O."

Article

Baird, R.D., Bermejo de Las Heras, B., Ruiz-Borrego, M. et al. (20 more authors) (2025) Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1. Clinical Cancer Research, 31 (20). pp. 4244-4254. ISSN 1078-0432

Hamilton, E., Oliveira, M., Turner, N. et al. (18 more authors) (2024) A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Annals of Oncology, 35 (8). pp. 707-717. ISSN 0923-7534

Robertson, J.F.R., Coleman, R.E. orcid.org/0000-0002-4275-1043, Cheung, K.-L. et al. (21 more authors) (2020) Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical Cancer Research, 26 (7). pp. 1574-1585. ISSN 1078-0432